However, according to a case–controlled study by Ganesh Raghu et al., there is no significant association between CCL18 concentration at baseline and the rate of disease progression in IPF patents, indicating that the baseline value of CCL18 cannot predict disease progression [87]. Here, CCL18 is linked to idiopathic pulmonary fibrosis.